Clinical Trial

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2028-01 -> 2027-08 2026-08-08
minor Completion moved earlier: 2028-01 -> 2027-08 2026-08-08
Trial Details
NCT Number NCT07264634
Lead Sponsor Ascendis Pharma A/S
Conditions Hypoparathyroidism
Enrollment 10 participants
Start Date 2026-03-19
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-07